Outcomes following implantation of the biolimus A9‐eluting Bio<scp>M</scp>atrix coronary stent: Primary analysis of the e‐<scp>B</scp>io<scp>M</scp>atrix registry

Urban, Philip; Valdés, Mariano; Menown, Ian; Eberli, Franz R.; Alhaddad, Imad A.; Hildick‐Smith, David; Iosseliani, David G.; Roffi, Marco; Oldroyd, Keith G.; Kalloudi, Erifyli; Eerdmans, Pedro; Berland, Jacques; Kleber, Franz X.

doi:10.1002/ccd.25892

Cited by 13 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to the incidence of definite and probable stent thrombosis, a very low rate (0.4%) at 1 year, was recorded in the present registry, which is again in line with the findings of SPIRIT V (0.6%) , the European Ebiomatrix registry (0.6%) and Nobori 2 (0.8%) at 1 year and with previously reported results in selected recipients of the Synergy stent (0.4%) , in unselected cohorts of the Resolute registry (0.9%) and in patients treated with the ABSORB BVS (1.0%) . In addition, the rates of very late thrombosis reported in both the French and European E‐Biomatrix registries are also quite similar (0.3% and 0.2%, respectively).…”

Section: Discussionsupporting

confidence: 92%

“…Indeed, the rate of MACE reported in recipients of the Xience Stent in the SPIRIT V study was 5.1% (excluding stroke). It was 3.9% (excluding stroke) in the Nobori 2 study and 4.5% in the e‐BioMatrix Registry conducted in Europe . In the Resolute all‐comer registry evaluating a zotarolimus‐eluting stent with a biocompatible polymer, the primary endpoint (cardiac death and target vessel MI at 1 year) was 4.3% and TLR was 3.5%.…”

Section: Discussionmentioning

confidence: 99%

“…A multi‐center registry was conducted in Europe to investigate in a large population of all‐comer patients, the reproducibility of the results achieved with the BES in the LEADERS trial.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and efficacy outcomes of 3rd generation DES in an all‐comer population of patients undergoing PCI: 12‐month and 24‐month results of the e‐Biomatrix French registry

Maupas¹,

Lipiecki²,

Levy

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

ObjectivesThe French Ebiomatrix registry aimed to confirm the results of the Leaders trial in an all‐comer population in France.BackgroundThe Leaders trial showed the Biolimus‐eluting‐sent (BES) to be equivalent to the Cypher stent in terms of safety and efficacy at 1 year and superior regarding stent thrombosis after 1 year.MethodsBES recipients were enrolled in 42 French centers with up to 24‐month clinical follow up.Results2365 patients were included. Mean age: 65.7 ±11.2 years, 76.1% males, 31.8% had diabetes, 36.5% ACS (28.7% non‐ST‐elevation MI and 7.8% with ST‐elevation MI). 1.7 ± 1.0 stents/patient were implanted and procedural success was 99.5%. 12‐month follow‐up was completed in 94.3% patients and 24 months in 91.4%. MACCE rates at 12 and 24 months were 5.8% and 9% (all cause‐death 1.5% and 2.2%; stent thrombosis definite/probable 0.4% and 0.6%), respectively. MACCE were not significantly higher in diabetic patients compared with non‐diabetics but cardiac death was higher (1.6% vs. 0.6%, P = 0.01 at 1 year and 1.9% vs. 0.6, P = 0.005 at 2 years) as was stent thrombosis (0.9% vs. 0.2%, P = 0.009 and 1.2 vs. 0.3% P = 0.008). Compared with non‐ACS patients, MACCE was significantly higher in the ACS subgroup (7.5% vs. 4.8%, P = 0.001 at 1 year and 10.3% vs.8.1%, P = 0.07 at 2 years).ConclusionIn this large real‐world registry, the BES with biodegradable polymer showed excellent acute and mid‐term outcomes with a 5.8% and 9% rate of MACCE at one and 2 years and a very low rate of stent thrombosis between 1 and 2 years (0.2%), thus demonstrating the replicability of the LEADERS trial in a registry population. © 2017 The Authors Catheterization and Cardiovascular Interventions Published by Wiley Periodicals, Inc.

show abstract